Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma [Phase 2]
This document announces a Phase 2 clinical trial evaluating JNJ-79635322 in relapsed or refractory multiple myeloma and notes that it is cur…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma [Phase 1]
A Phase 1 clinical trial evaluating the safety and tolerability of OPN-6602 in subjects with relapsed or refractory multiple myeloma is curr…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma [Phase 1]
This Phase 1 trial evaluates JNJ-79635322 in combination with daratumumab, with or without lenalidomide, or in combination with pomalidomide…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]
Phase 1 clinical trial assessing pharmacokinetics, safety, and efficacy of cevostamab in Chinese participants with relapsed or refractory mu…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel [Phase 4]
A Phase 4 long-term follow-up trial for patients who were previously treated with cilta-cel (cilta-cabtagene autoleucel) for multiple myelom…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Daratumumab [Phase 3]
A Phase 3 clinical trial investigating daratumumab for multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
A clinical trial update about outcomes in relapsed/refractory multiple myeloma patients treated with T-cell redirectors outside of clinical …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma [Phase 2]
Phase 2 clinical trial update comparing Dara-SVD (daratumumab, selinexor, bortezomib, dexamethasone) with Dara-RVD (daratumumab, lenalidomid…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
A multicenter protocol to improve access and distribution of unlicensed cryopreserved cord blood units, with the study currently recruiting.…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma [Phase 1]
This clinical trial update describes a Phase 1 study evaluating teclistamab in combination with other anticancer therapies for multiple myel…
-
CLINICAL_TRIALS other · 2026-04-13Clinical Trial Update: CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma. [Phase 1]
Clinical trial update for CPD-DARA in relapsed/refractory multiple myeloma; the Phase 1 study is currently active but not recruiting.
-
EMA approval · 2026-04-09EMA Authorised: Neofordex (dexamethasone) — THERAVIA
The European Medicines Agency has authorised Neofordex, a dexamethasone product from THERAVIA, for use in the treatment of multiple myeloma …
-
EMA approval · 2026-04-09EMA Authorised: Darzalex (daratumumab) — Janssen-Cilag International N.V.
The EMA authorised Darzalex (daratumumab) by Janssen-Cilag International N.V. for multiple myeloma, with orphan medicine status and accelera…
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) [Phase 1]
This update reports results from a Phase 1 study evaluating subcutaneous TAK-079 added to standard-of-care regimens in adults with newly dia…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
The document provides a clinical trial update from the University of Miami describing two distinct precursor states of multiple myeloma—prog…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma
A clinical trial is evaluating Zn-DDC to target the Hypoxia-NFkappaB-CSCs pathway in multiple myeloma. Recruitment is ongoing.
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms [EARLY_Phase 1]
An early-phase study of CAR 70-BCMA CAR-T cells for relapsed or refractory plasma cell neoplasms, with recruitment not yet started.
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy [Phase 3]
Phase 3 study comparing Daratumumab-VELCADE-Lenalidomide-Dexamethasone (D-VRd) vs VELCADE-Lenalidomide-Dexamethasone (VRd) in untreated mult…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction [Phase 2]
A Phase 2 study evaluating frontline induction with carfilzomib, lenalidomide, and dexamethasone in multiple myeloma has completed.
-
EMA approval · 2026-04-08EMA Authorised: Blenrep (belantamab mafodotin) — GlaxoSmithKline Trading Services Limited
The European Medicines Agency has authorised Blenrep (belantamab mafodotin) for the treatment of multiple myeloma. The decision date is 05 F…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy [Phase 3]
This Phase 3 trial compares D-VRd (daratumumab, bortezomib, lenalidomide, dexamethasone) with VRd in untreated multiple myeloma patients not…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation [EARLY_Phase 1]
This early-phase 1 clinical trial investigates CAR19BCMA CAR-T cells for relapsed or refractory plasma cell neoplasms and lymphomas/leukemia…
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma [Phase 2]
Phase 2 clinical trial evaluating daratumumab in combination with dexamethasone for resistant or refractory multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma [Phase 2]
Completed Phase 2 study evaluating weekly carfilzomib with melphalan and prednisone in untreated elderly patients with symptomatic multiple …
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study
A multicenter prospective study aims to predict response to selinexor-based therapy in relapsed/refractory multiple myeloma and is currently…